Company Overview

Biotricity, Inc. is a U.S.-based medical technology company operating in the remote cardiac monitoring, diagnostic services, and consumer healthcare technology industries. The company focuses on developing and commercializing wearable and cloud-connected devices that enable continuous cardiac monitoring, data analytics, and remote patient management. Its offerings are designed to support early detection, diagnosis, and long-term management of cardiovascular conditions, primarily within outpatient and home-based care settings.

Biotricity generates revenue through a combination of device sales, recurring monitoring service fees, and data-driven diagnostic services. Its core customer segments include healthcare providers, diagnostic testing facilities, physician practices, and increasingly direct-to-consumer health technology users. The company positions itself as an integrated platform provider combining hardware, software, and clinical services, emphasizing continuity of care and recurring revenue models. Biotricity was founded in 2012 and has evolved from a single-product cardiac monitoring company into a multi-vertical healthcare technology platform through internal development and acquisitions.

Business Operations

Biotricity operates through multiple business lines centered on cardiac diagnostics, remote monitoring, and consumer health. Its primary operating segments include Biotricity Healthcare, which delivers clinical-grade cardiac monitoring devices and diagnostic services, and Biotricity Consumer, which focuses on consumer-oriented wearable health products. Revenue is generated through device placements, per-test diagnostic fees, and subscription-based monitoring services tied to long-term patient use.

The company controls proprietary wearable technologies, cloud-based data platforms, and analytics software used to collect and interpret cardiac data. Operations are primarily based in the United States, with services delivered through a network of healthcare providers and diagnostic partners. Biotricity also operates FDA-cleared cardiac monitoring solutions and maintains in-house capabilities for data analysis and reporting. Certain aspects of diagnostic interpretation rely on contracted physician networks; detailed disclosure on specific joint ventures is limited, and some partnership structures are not fully delineated in public filings.

Strategic Position & Investments

Biotricity’s strategic direction emphasizes expanding its recurring revenue base, increasing utilization of long-term cardiac monitoring solutions, and scaling its consumer health portfolio. Growth initiatives include cross-selling services across its clinical and consumer platforms and increasing penetration within outpatient cardiology and primary care markets. The company has pursued acquisitions to broaden its product portfolio and vertical integration, including the acquisition of Bioflux, which strengthened its mobile cardiac telemetry and diagnostic capabilities.

The company has invested in emerging areas such as extended-wear biosensors, cloud-based healthcare analytics, and consumer-facing health monitoring devices. Notable subsidiaries include Biotricity Healthcare, Biotricity Consumer, and Biotres, each supporting different aspects of its platform strategy. While management has articulated a long-term vision of becoming an end-to-end cardiac care technology provider, some future product expansion timelines remain subject to regulatory and market adoption factors.

Geographic Footprint

Biotricity is headquartered in the United States, with its principal executive offices located in California. Its operational and commercial activities are predominantly concentrated in North America, where it markets and supports its clinical diagnostic services and consumer products. The company’s regulatory clearances and reimbursement exposure are primarily tied to the U.S. healthcare system.

International presence is limited, with no material revenue contribution disclosed from outside North America as of the most recent public filings. While management has indicated interest in international market expansion, particularly in regions with growing demand for remote healthcare technologies, publicly available data indicates that global operations remain at an early or exploratory stage.

Leadership & Governance

Biotricity was founded by Waqaas Al-Siddiq, who continues to play a central role in shaping the company’s strategic vision. Leadership emphasizes vertical integration, data-driven healthcare delivery, and long-term recurring revenue models within digital health. The company is governed by a board of directors with experience across healthcare, technology, and capital markets.

Key executives include:

• Waqaas Al-Siddiq – Founder, Chairman & Chief Executive Officer
• Bryan Ware – Chief Financial Officer
• Richard Rau – Chief Operating Officer
• Prabhu Ramachandran – Chief Technology Officer

The leadership team’s philosophy centers on leveraging technology to decentralize cardiac care and improve patient outcomes while maintaining regulatory compliance and clinical validation. Some executive role scopes and tenure details vary slightly across public disclosures; however, core leadership positions are consistently reported across available sources.